Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition and demonstrated high selectivity over other PDE families.
Scientists at Institució Catalana de Recerca i Estudis Avançats and Universitat de Barcelona have identified three-prime repair exonuclease 2 (TREX2) inhibitors reported to be useful for the treatment of psoriasis, atopic dermatitis and ichthyosis.
Enanta Pharmaceuticals Inc. has announced the expansion of its immunology portfolio with the nomination of a new development candidate and the introduction of a new discovery program.
Secretome Therapeutics Inc. has closed a $20.4 million round of financing to support its development of therapies derived from neonatal cardiac progenitor cells.
Blood dendritic cell antigen 2 (BDCA2) is expressed in plasmacytoid dendritic cells. These cells’ overproduction of type I interferon is closely linked to the pathogenesis of systemic lupus erythematosus and other autoimmune diseases.
Protagonist Therapeutics Inc. has selected PN-881, an oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases.
Trex Bio Inc. has closed an oversubscribed $84 million series B financing round to support development of its pipeline of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
RSS
